

SUMO2/3 Antibody (C-term)
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP1224a**Specification****SUMO2/3 Antibody (C-term) - Product Information**

Application	IF, WB, IHC-P,E
Primary Accession	P55854
Other Accession	Q7SZ22 , Q5XIF4 , Q9Z172 , Q6DI05 , Q17QV3 , P61959 , P61958 , P61957 , Q2PFW2 , P61956 , Q6DHL4 , Q6LDZ8 , Q5ZJM9 , P61955 , Q6NV25 , Q6GPW2 , Q7ZTK7
Reactivity Predicted	Human, Mouse, Rat Xenopus, Zebrafish, Bovine, Chicken, Hamster, Monkey, Pig
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	49-81

SUMO2/3 Antibody (C-term) - Additional Information**Gene ID** 6612**Other Names**

Small ubiquitin-related modifier 3, SUMO-3, SMT3 homolog 1 {ECO:0000312|HGNC:HGNC:11124}, SUMO-2, Ubiquitin-like protein SMT3A, Smt3A, SUMO3 (http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=11124)
target="_blank">HGNC:11124)

Target/Specificity

This SUMO2/3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 49-81 amino acids from the C-terminal region of human SUMO2/3.

Dilution

IF~~1:100
WB~~1:2000
IHC-P~~1:50~100

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

SUMO2/3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

SUMO2/3 Antibody (C-term) - Protein Information

Name SUMO3 ([HGNC:11124](#))

Function Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4 (PubMed:[11451954](#), PubMed:[18538659](#), PubMed:[21965678](#)). Plays a role in the regulation of sumoylation status of SETX (PubMed:[24105744](#)).

Cellular Location

Cytoplasm. Nucleus. Nucleus, PML body

Tissue Location


Expressed predominantly in liver.

SUMO2/3 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

SUMO2/3 Antibody (C-term) - Images




Fluorescent image of SH-SY5Y cells stained with SUMO2/3 Antibody (C-term) (Cat#AP1224a).


AP1224a was diluted at 1:100 dilution. An Alexa Fluor 488-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody (green). Cytoplasmic actin was counterstained with Alexa Fluor® 555 conjugated with Phalloidin (red).



Fluorescent image of HeLa cells stained with SUMO2/3 Antibody (C-term) (Cat#AP1224a). AP1224a was diluted at 1:100 dilution. An Alexa Fluor 488-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody (green). Cytoplasmic actin was counterstained with Alexa Fluor® 555 conjugated with Phalloidin (red).



All lanes : Anti-SUMO2/3 Antibody (C-term) at 1:2000 dilution Lane 1: SH-SY5Y whole cell lysate Lane 2: HeLa whole cell lysate Lane 3: Jurkat whole cell lysate Lane 4: HL-60 whole cell lysate Lane 5: Mouse cerebellum tissue lysate Lane 6: Mouse liver tissue lysate Lane 7: Rat liver tissue lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 12 kDa Blocking/Dilution buffer: 5% NFDm/TBST.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

SUMO2/3 Antibody (C-term) - Background

SUMO2 and SUMO3 are members of the SUMO (small ubiquitin-like modifier) protein family. This protein family functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. In vertebrates, three members of the SUMO family have been described, SUMO 1 and the functionally distinct homologues SUMO 2 and SUMO 3. SUMO modification sites present in the N terminal regions of SUMO 2 and SUMO 3 are utilized by SAE1/SAE2 (SUMO E1) and Ubc9 (SUMO E2) to form polymeric chains of SUMO 2 and SUMO 3 on protein substrates, a property not shared by SUMO 1.

SUMO2/3 Antibody (C-term) - References

Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).

Lapenta, V., et al., Genomics 40(2):362-366 (1997).

SUMO2/3 Antibody (C-term) - Citations

- [Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SEN2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition](#)
- [TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease](#)
- [The SUMOylation landscape of renal cortical collecting duct cells.](#)
- [HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.](#)
- [TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RAR \$\alpha\$ and Inhibition of p53-Mediated Senescence.](#)
- [Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.](#)
- [Signaling via the IL-20 receptor inhibits cutaneous production of IL-1 \$\beta\$ and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus.](#)
- [PKC \$\zeta\$ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation.](#)
- [Lysine deacetylation in ischaemic preconditioning: the role of SIRT1.](#)
- [Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation.](#)
- [Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of](#)

[protein and lipid homeostasis of functionally diverse but linked pathways in response to oxidative stress.](#)

- [Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity.](#)
- [SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity.](#)